Clinical practice guideline on bladder cancer (Part II)

Abstract

Bladder cancer (BC) is an increasingly common malignancy in China, with an incidence rate of 5.80 per 100 000 in 2015, making it the thirteenth most common cancer in the country. This trend underscores the urgent need for standardized diagnosis and treatment protocols. In terms of treatment, approaches for bladder cancer vary based on the cancer's stage and pathology, as well as the patient's overall health. Notably, non‐muscle‐invasive BC (NMIBC) confined to the mucosa (Ta) and lamina propria (T1) without invading the muscle represents about 75% of all BC cases. Succeeding the first part of the guideline, this part of the clinical practice guideline focuses on NMIBC. It details risk classifications and treatment options, including both surgical procedures and posttransurethral resection of the bladder tumor intravesical instillations. Special attention is given to the treatment strategies for carcinoma in situ. The guideline also covers the recommended follow‐up procedures for patients with NMIBC, underscoring the need for thorough and continuous care management.